Clinical Trials Logo
  1. Home
  2. Non-Small-Cell Lung Carcinoma
  3. NCT00087711

A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Non Small Cell Lung Carcinoma Clinical Trial

Official title:
A Randomized Phase 3 Trial of ALIMTA and Cisplatin Versus GEMZAR and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Clinical Trial Summary

This study is a randomized Phase 3 study comparing pemetrexed and cisplatin combination to gemcitabine and cisplatin for the treatment of Non Small Cell Lung Cancer (NCSLC). Gemcitabine plus cisplatin is currently the standard of care for NSCLC. It is thought that pemetrexed plus cisplatin may be as effective and may have fewer side effects than the standard of care.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00087711
Study type Interventional
Source Eli Lilly and Company
Contact
Status Completed
Phase Phase 3
Start date July 2004
Completion date March 2008
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01229150 - Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... Phase 2
Terminated NCT00592007 - Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer Phase 2
Completed NCT00199758 - Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer Phase 2
Completed NCT01999738 - Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Phase 1
Completed NCT01941316 - Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Phase 1/Phase 2
Completed NCT00111839 - Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer Phase 2
Completed NCT00181532 - Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC Phase 2
Completed NCT00890903 - Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC) N/A
Completed NCT00864266 - Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer N/A
Completed NCT00635791 - Phase I Study of Vorinostat and Sorafenib in Advanced Cancer Phase 1
Recruiting NCT00727350 - Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma. Phase 2
Completed NCT01209520 - Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy N/A
Active, not recruiting NCT00759382 - Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
Completed NCT00252798 - ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer Phase 1
Completed NCT02938624 - Anti PD-1 Neo-adjuvant Treatment for NSCLC Phase 1
Terminated NCT00661011 - Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy Phase 2
Completed NCT00608868 - SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients Phase 4
Terminated NCT00234468 - Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC Phase 3
Completed NCT00193921 - Chemoradiotherapy in Patients With Localised Lung Cancer Phase 2
Completed NCT00252746 - ZD6474 Phase IIa Dose Finding Multicentre Study Phase 2